Experience with intraperitoneal cisplatin and etoposide and i.v. sodium thiosulphate protection in ovarian cancer patients with either pathologically complete response or minimal residual disease
Open Access
- 1 December 1997
- journal article
- clinical trial
- Published by Elsevier in Annals of Oncology
- Vol. 8 (12) , 1235-1241
- https://doi.org/10.1023/a:1008296202198
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Phase II trial for intraperitoneal cisplatin plus intravenous sodium thiosulphate in advanced ovarian carcinoma patients with minimal residual disease after cisplatin-based chemotherapy—a phase II study of the EORTC gynaecological cancer cooperative groupEuropean Journal Of Cancer, 1994
- Oral etoposide is active against platinum-resistant epithelial ovarian cancer.Journal of Clinical Oncology, 1994
- Debulking and intervention surgeryAnnals of Oncology, 1993
- Salvage Intraperitoneal Therapy of Ovarian Cancer Employing Cisplatin and Etoposide: A Gynecologic Oncology Group StudyGynecologic Oncology, 1993
- Intraperitoneal High-Dose Cisplatin and Etoposide with Systemic Thiosulfate Protection in Second-Line Treatment of Advanced Ovarian CancerGynecologic Oncology, 1993
- Long-term survival in ovarian cancerEuropean Journal of Cancer and Clinical Oncology, 1991
- Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Advanced Ovarian Cancer Trialists Group.BMJ, 1991
- Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. The Ovarian Cancer Meta-Analysis Project.Journal of Clinical Oncology, 1991
- VP-16 and cisplatin as first-line therapy for small-cell lung cancer.Journal of Clinical Oncology, 1985
- Etoposide salvage therapy for refractory germ cell tumors: an updateCancer Treatment Reviews, 1982